Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal

Yusimry Biosimilar Divested To Hong Kong King-Friend For $40m Upfront

 
• By Dean Rudge

Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.

Investing in new business while divesting in old industry with an old tree shaped as a finance pie chart graph funding a green tree
• Source: Shutterstock

Meitheal Pharmaceuticals has ushered in what it believes is a “pivotal moment,” picking up its fifth biosimilar product and the first one on the market after gaining the exclusive US commercial rights to Coherus BioSciences’ Yusimry (adalimumab-aqvh) biosimilar to Humira.

The US-based injectables specialist’s parent company, Hong Kong King-Friend (HKF), has paid $40m upfront to Coherus for the worldwide rights to Yusimry, including “substantially all assets related to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business